NCT01132989View on ClinicalTrials.gov

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Cutaneous T Cell Lymphoma
Interventions
DRUG

Lenalidomide

Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle

Trial Locations (1)

33136

RECRUITING

Florida Academic Dermatology Center, Miami

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Florida Academic Dermatology Centers

OTHER